News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The country is sixth among the most affected countries by active cases
Biocon has reported consolidated financial results for the period ended December 31, 2021
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Ind-Ra expects revenue growth of over 12% in 2022.
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Subscribe To Our Newsletter & Stay Updated
